Sign in

    Max Jacobs

    former Managing Partner and Director of Research for North America at Edison Investment Research

    Max Jacobs is a former Managing Partner and Director of Research for North America at Edison Investment Research, specializing in healthcare and biotechnology equity coverage. At Edison, he covered emerging biopharmaceutical companies including InMed Pharmaceuticals, delivering in-depth sector insights, though publicly available performance metrics such as analyst rankings or returns are limited. Jacobs began his career in equity research, rising through analytical roles to lead research in North America at Edison before moving to a senior position at Russo Partners as Head of Investor Relations. He holds the Chartered Financial Analyst (CFA) designation, reflecting his strong professional credentials and expertise in investment analysis.

    Max Jacobs's questions to InMed Pharmaceuticals (INM) leadership

    Max Jacobs's questions to InMed Pharmaceuticals (INM) leadership • Q4 2021

    Question

    Max Jacobs of Edison Investment Research inquired about the product launch timeline for new cannabinoids from BayMedica, the customer profile for its current CBC product, and the expected timing for an IND filing for the INM-088 glaucoma treatment.

    Answer

    President and CEO Eric Adams explained that guidance on new cannabinoid launches would follow the acquisition's close, but launches are expected in the coming quarters. He described the current CBC customer base as B2B, including wholesale distributors and product formulators. For INM-088, he confirmed the target for an IND filing is the second half of calendar 2022, pending toxicology studies and FDA meetings.

    Ask Fintool Equity Research AI